Purinergic Receptor P2Y, G-Protein Coupled, 12 (P2RY12) ELISA Kits

The product of P2RY12 belongs to the family of G-protein coupled receptors. Additionally we are shipping P2RY12 Antibodies (43) and P2RY12 Proteins (5) and many more products for this protein.

list all ELISA KIts Gene Name GeneID UniProt
P2RY12 70839 Q9CPV9
P2RY12 64805 Q9H244
P2RY12 64803 Q9EPX4
How to order from antibodies-online
  • +1 877 302 8632
  • +1 888 205 9894 (toll-free)
  • Order online
  • orders@antibodies-online.com

Top P2RY12 ELISA Kits at antibodies-online.com

Showing 10 out of 25 products:

Catalog No. Reactivity Sensitivity Range Images Quantity Supplier Delivery Price Details
Human 0.054 ng/mL 0.15 ng/mL - 10 ng/mL 96 Tests Log in to see 13 to 16 Days
Rat 0.1 ng/mL 10-250 ng/mL   96 Tests Log in to see 15 to 18 Days
  96 Tests Log in to see 15 to 18 Days
  96 Tests Log in to see 15 to 18 Days
  96 Tests Log in to see 15 to 18 Days
Guinea Pig
  96 Tests Log in to see 15 to 18 Days
  96 Tests Log in to see 15 to 18 Days
  96 Tests Log in to see 15 to 18 Days
  96 Tests Log in to see 15 to 18 Days
  96 Tests Log in to see 15 to 18 Days

More ELISA Kits for P2RY12 Interaction Partners

Mouse (Murine) Purinergic Receptor P2Y, G-Protein Coupled, 12 (P2RY12) interaction partners

  1. OC formation was efficiently restored by addition of adenosine diphosphate, a P2Y12 agonist, as well as by addition of CysLT. Furthermore, similar to montelukast, P2Y12 blockade by a pharmacological inhibitor or siRNAs suppressed OC differentiation

  2. Our finding demonstrated that genetic deletion of P2Y12 receptor broke the balance of Th subtypes by affecting the cytokine profile of bone marrow-derived dendritic cells and resulted in the aggravated experimental autoimmune encephalomyelitis, which suggested that P2Y12 may be a potential target in treating multiple sclerosis.

  3. Study demonstrates a complementary role between TSSC6 and P2Y12 receptor in platelets in regulating 'outside in' integrin alphaIIbbeta3 signalling thrombus growth and stability.

  4. Findings offer insight into positive regulation of Akt signaling through P2Y12 phosphorylation as well as MAPK signaling in platelets by ASK1.

  5. CLEC-2 and P2Y12 are required for CpG ODN-induced platelet activation and thrombosis, and might be targeted to prevent adverse events in patients at risk.

  6. Nucleotide transmitters ATP and ADP mediate intercellular calcium wave communication via P2Y12/P2Y13 receptors among BV-2 microglia.

  7. findings not only revealed the critical role of P2Y12 in Th17 differentiation and EAE pathogenesis, but also suggested the promising potential of P2Y12 antagonists in the treatment of autoimmune diseases

  8. P2y12 Receptor Promotes Pressure Overload-Induced Cardiac Remodeling via Platelet-Driven Inflammation in Mice.

  9. In P2Y12(-/-) mice, the growth of syngeneic ovarian cancer tumors was reduced by >85% compared with wild-type (WT) mice. In contrast, there was no difference in tumor growth between P2Y1(-/-) and WT mice.

  10. Vessel wall P2Y12 receptor, which promotes VSMCs migration through cofilin dephosphorylation, plays a critical role in the development of atherosclerotic lesions.

  11. P2Y12 null mice are refractory to sepsis-induced lung injury, suggesting a key role for activated platelets and the P2Y12 receptor during sepsis.

  12. excessive mechanical stress may induce a sustained release of ADP and promote SMC senescence via P2ry12-dependent sustained Ras activation, thereby contributing to excessive inflammation and degeneration, which provides insights into TAAD formation and progression.

  13. AHR and airway inflammation in a mouse model of asthma. P2Y12 can be a novel therapeutic target to the suppression of eosinophils in asthma.

  14. quinine/bupivacaine-sensitive potassium channels are the functional effectors of the P2Y12R-mediated signaling in microglia activation following neuronal injury

  15. Calcium-mediated purinergic receptors regulate the migration and phagocytic ability of microglia during post-natal brain development.

  16. Disrupting P2Y12 alters the microglial response to monocular deprivation and abrogates ocular dominance plasticity.

  17. P2RY12-mediated activation of juxtavascular microglial cells contributes to the rapid closure of small openings in the BBB.

  18. study reports robust involvement of P2Y12R in inflammatory pain: anti-hyperalgesic effect of P2Y12R antagonism could be mediated by the inhibition of both central and peripheral cytokine production and involves alpha7-receptor mediated efferent pathways

  19. demonstrating that these P2Y12 inhibitors may not be effective in preventing early disease

  20. indicate that P2Y12R undergoes slow desensitization; ADP-P2Y12 signaling is tightly regulated by Entpd1/Nt5e activity and adenosine receptors

Human Purinergic Receptor P2Y, G-Protein Coupled, 12 (P2RY12) interaction partners

  1. Minor allele frequencies (MAF) in a Puerto Rican population were 46% for PON1 (rs662), 41% for ABCB1 (rs1045642), 14% for CYP2C19*17, 13% for CYP2C19*2, 12% for P2RY12-H2 and 0.3% for CYP2C19*4. No carriers of the CYP2C19*3 variants were detected. All alleles and genotype proportions were found to be in HardyWeinberg equilibrium (HWE).

  2. Downregulation of the P2Y12 receptor in the superior cervical ganglia after myocardial ischemia may improve cardiac function by alleviating the sympathoexcitatory reflex

  3. TRAP-6 induced platelet activation leads to an elevation of purinergic receptor P2Y12 expression.

  4. upon platelet activation with ADP, the number of GP IIb-IIIa and P2Y12 receptors increases, which may serve as evidence of these proteins being synthesized in the activated platelets

  5. In patients with type 2 diabetes, the presence of chronic kidney disease is associated with hyperreactive platelets and a dysfunctional status of the P2Y12 receptor signalling pathway.

  6. We documented a different effect of CYP2C19 and P2Y12 receptor polymorphisms on platelet reactivity and cardiovascular outcome in coronary artery disease patients after percutaneous coronary intervention on clopidogrel treatment. Importantly, increased platelet reactivity adversely affects the cardiovascular outcome independently of the studied polymorphisms.

  7. Findings offer insight into positive regulation of Akt signaling through P2Y12 phosphorylation as well as MAPK signaling in platelets by ASK1.

  8. Genomic association study identified deleterious rare variants in P2RY12 in patients with ischemic stroke.

  9. Expression of platelet hsa-miR-223 increased and P2RY12 mRNA reduced in type 2 diabetic patients following ET non-significantly.

  10. The meta-analysis shows a potential of association between P2RY12 gene polymorphisms and higher risks of composite ischemic events for coronary artery disease patients treated with clopidogrel. [review]

  11. CLEC-2 and P2Y12 are required for CpG ODN-induced platelet activation and thrombosis, and might be targeted to prevent adverse events in patients at risk.

  12. miR-223, miR-26b, miR-126 and miR-140 are expressed at a lower level in platelets and megakaryocytes in type 2 diabetics causing up-regulation of P2RY12 and SELP mRNAs that may contribute to adverse platelet function.

  13. The DHA - naringenin hybrid presented triple antiplatelet activity simultaneously targeting PAR-1, P2Y12 and COX-1 platelet activation pathways

  14. The results suggest that P2Y12 is a useful marker for the identification of human microglia throughout the lifespan. Moreover, P2Y12 expression might help to discriminate activated microglia and infiltrating myeloid cells from quiescent microglia in the human CNS.

  15. P2RY12, the gene related to thrombogenesis was differentially expressed between the left atrium and right atrium in Sinus rhythm and Atrial fibrillation. Therefore, the changes in the expression of these genes were likely involved in the pathophysiology of AF-related thrombus formation.

  16. Abnormalities of P2Y12 receptor include congenital deficiencies or high activity in diseases like diabetes mellitus and chronic kidney disease, exposing such patients to a prothrombotic condition. (Review)

  17. Data suggest that PAR4 and P2Y12 heterodimer internalization/endocytosis is required for beta-arrestin-2 recruitment to endosomes and up-regulation of Akt signaling; activation of PAR4 but not of P2Y12 drives internalization of the PAR4-P2Y12 heterodimer. (PAR4 = protease-activated receptor 4; P2Y12 = purinergic receptor P2Y, G-protein coupled, 12 protein; Akt = proto-oncogene protein c-akt)

  18. Studies indicate that purinergic receptor P2Y12 (P2Y12 receptor) gene C34T and G52T polymorphism might be a risk factor for the poor response to the platelet in patients on clopidogrel therapy.

  19. studies describe 2 novel modes of action of ticagrelor, inhibition of platelet ENT1 and inverse agonism at the P2Y12R that contribute to its effective inhibition of platelet activation.

  20. apart from the established association of the CYP2C19 *2 and *3 LOF alleles with high on-treatment platelet reactivity (HTPR), haplotypes of P2RY12 rs6798347, rs6787801, rs6801273, and rs6785930 rather than rs2046934 (T744C) that related to pharmacodynamics of clopidogrel in patients with ACS were independently associated with HTPR

P2RY12 Antigen Profile

Antigen Summary

The product of this gene belongs to the family of G-protein coupled receptors. This family has several receptor subtypes with different pharmacological selectivity, which overlaps in some cases, for various adenosine and uridine nucleotides. This receptor is involved in platelets aggregation, and is a potential target for the treatment of thromboembolisms and other clotting disorders. Two transcript variants encoding the same isoform have been identified for this gene.

Gene names and symbols associated with P2RY12

  • purinergic receptor P2Y, G-protein coupled 12 (P2ry12) antibody
  • purinergic receptor P2Y12 (P2RY12) antibody
  • purinergic receptor P2Y12 (P2ry12) antibody
  • 2900079B22Rik antibody
  • 4921504D23Rik antibody
  • ADPG-R antibody
  • BDPLT8 antibody
  • HORK3 antibody
  • P2T(AC) antibody
  • P2Y(12)R antibody
  • P2Y(AC) antibody
  • P2Y(ADP) antibody
  • P2Y(cyc) antibody
  • P2y12 antibody
  • SP1999 antibody

Protein level used designations for P2RY12

P2Y purinoceptor 12 , ADP-glucose receptor , G-protein coupled receptor SP1999 , Gi-coupled ADP receptor HORK3 , P2Y12 platelet ADP receptor , purinergic receptor P2RY12 , putative G-protein coupled receptor

70839 Mus musculus
64805 Homo sapiens
64803 Rattus norvegicus
442958 Canis lupus familiaris
Selected quality suppliers for P2RY12 (P2RY12) ELISA Kits
Did you look for something else?